8.

Abstract

This study aimed to compare the effectiveness of fingolimod with interferon beta or glatiramer acetate (IFN/GA) as second line agents in reducing relapse rates, accumulation of disability and increasing treatment persistence in active multiple sclerosis. Data was extracted from MSBase, an international multiple sclerosis patient registry. Patients were identified who had failed first line therapy with IFN/GA and had switched to either fingolimod or another IFN/GA preparation. Propensity score matching was used to match patients in each treatment arm by baseline clinical and demographic characteristics. Paired Cox proportional hazards models was used to evaluate differences in time to first r..